Target WP6 - Ricapps

The network

research programme

03

WP 6. To characterise chronicity, multimorbidity and frailty in primary care and in continuity of care processes.

Coordinator

Alexandra Prados

EpiChron Research Group

RD21/0016/0019

sprados.iacs@aragon.es

Participating Groups

EpiChron. IP:

Alexandra Prados (RD21/0001/0019)

AQUAS. IP:

Mireia Espallargues (RD21/0001/0007)

GRAP-caIB. IP:

Alfonso Leiva (RD21/0001/0009)

Kronikgune - 2. IP:

Amaia Bilbao (RD21/0001/0011)

Canary Islands. IP:

Lilisbeth Perestelo (RD21/0001/0013)

Málaga. IP:

Maximino Redondo (RD21/0001/0015)

Navarra. IP:

Berta Ibáñez (RD21/0001/0016)

Kronikgune - 1. IP:

Susana García (RD21/0001/0017)

IMIM. IP:

María Sala (RD21/0001/0020)

Galicia. IP:

Francisco Gude (RD21/0001/0022)

Alicante. IP:

Francisco Gil (RD21/0001/0024)

Madrid - AP. IP:

César Minué (RD21/0001/0026)

Madrid. IP:

Isabel del Cura (RD21/0001/0027)

F. Avedis Donabedian. IP:

Carola Orrego (RD21/0001/0028)

GRenSSAP. IP:

Anna Berenguera Anna Berenguera

ISCiii. IP:

Joao Forjaz (RD21CIII/0003/0002)

Research lines

Line 1 To characterise the clinical epidemiology and the impact on health outcomes of multimorbidity. This line of research aims to provide robust scientific evidence on the onset, progression and impact of multimorbidity, focusing on describing how chronic diseases tend to cluster into multimorbidity patterns and on identifying variables associated with negative health outcomes in patients with multimorbidity. This line aims to raise awareness of multimorbidity among caregivers and to provide them with key evidence to help them care for these patients.

Task 1. To characterise the evolution of multimorbidity through large-scale population analysis and identify and clinically describe multimorbidity patterns in specific population groups.

Task 2. To identify the factors that have a negative impact on health outcomes in patients with multimorbidity to support the development of clinical prediction rules.

Line 2 To characterise the clinical epidemiology, comorbidity profiles and the factors affecting prognosis in patients with highly prevalent and relevant chronic diseases, including the patients’ perspective. This line aims to provide robust scientific evidence on the clinical epidemiology of relevant and highly prevalent chronic diseases and to support caregivers with clinical tools to improve the care of these patients and include their perspective.

Task 1. To characterise the clinical epidemiology and comorbidity of relevant and highly prevalent chronic diseases, including the patient’s perspective.

Task 2. To produce evidence to support decision-making based on the identification and measurement of risk factors for a poor prognosis in patients with relevant specific chronic diseases.

Line 3 To identify risk factors and determinants of frailty and low intrinsic capacity, and develop instruments to identify groups of high-risk patients. This line aims to provide robust scientific evidence on the characterisation and evaluation of frailty and the identification of risk determinants in older patients and those with specific chronic diseases, in order to improve and adapt their care.

Task 1. To characterise frailty and low intrinsic capacity and their impact on health, in order to support the development of instruments and tools to define and measure the state of frailty and low intrinsic capacity in clinical practice.

Line 4 To characterise the interactions between chronic and infectious diseases and analyse the health and social impact of infectious diseases on patients with chronic diseases. This line is dedicated to generating robust scientific evidence on the effects of infectious diseases on patients with chronic diseases and on high-risk groups (e.g. older people, pregnant women and their newborns).

Task 1. To identify the profiles of patients at greatest risk of severe infection and poor prognosis due to infectious diseases in general and, in particular, Covid-19 infection, with special attention to patients with chronic conditions, and to develop prediction tools.

Task 2. To characterise the impact of infectious diseases in general and, in particular, of Covid-19 infection in terms of outcomes for patients with chronic conditions, care, social needs, long-term effects in patients with long COVID, and vaccine safety.